chimeric antibodies

chi·mer·ic an·ti·bod·ies

antibodies that may have the FAB fragment from one species fused with FC fragment from another species.
Mentioned in ?
References in periodicals archive ?
Antibodies to chimeric antibodies (HACA) may be directed against a wide variety of epitopes in both the antigen combining site or framework epitopes in both the constant and variable regions of the immunoglobulin molecule.
This period of dynamic growth for humanized and fully human antibodies plus the continued rollout of antibody-drug conjugates (ADCs), also called immunoconjugates, is expected to result in stagnating sales of chimeric antibodies from 2011 through 2016.
Chimeric antibodies have been introduced in some assays with a view to eliminate interference from anti-mouse antibodies (2).
In addition, functional single chain antibodies, antibody fragments and chimeric antibodies may also be produced.
The new patent allows for a broad extension of the intellectual property to cover other chimeric antibodies or antibody-conjugates targeting the same antigen.
Vernon Oi and Sherry Morrison, of molecular methods for producing the "humanized" chimeric antibodies that are central to these highly successful therapies.
The body's immune system can recognize the mouse protein found in chimeric antibodies as foreign and launches an immune response in the form of infusion reactions, allergic reactions or anaphylaxis.
Human anti-chimeric antibodies have been detected in patients treated with chimeric antibodies (81), although in other studies (e.
The development focus of the industry is moving away from murine and chimeric antibodies, to humanized and, in particular, fully human technologies.
For example, chimeric antibodies are discussed in the chapter "Antibody Engineering" but are neither indexed nor defined.
However the limitation of the non-functional target approach is the need of conjugated or chimeric antibodies.
Additionally, our molecules were both humanized using AME's frAMEworks(TM) germline humanization technology and therefore may provide a reduced risk of immunogenicity when compared to the currently marketed chimeric antibodies.